Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04927572 | Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis | PHASE1 | COMPLETED | 21 | — | — | Oct 13, 2021 | Aug 9, 2022 | Aug 31, 2022 | 7 | United States, Australia |
| Arm | Type | Description |
|---|---|---|
| FMX114 | EXPERIMENTAL | - |
| Vehicle | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| FMX114 | DRUG | Active Comparator |
| Vehicle | OTHER | Placebo Comparator |
Inclusion Criteria: 1. Subjects must have the ability to understand and be willing to sign an informed consent form. 2. Aged ≥ 18 years, at time of screening visit. 3. Weight ≥ 40 kg, at time of screening visit. 4. Diagnosis of Atopic Dermatitix with a total body surface area (BSA) of AD involvemen...